Victor Deu - Grifols SA Co-CEO, Executive Director

GRFS Stock  USD 6.65  0.17  2.62%   

CEO

Mr. Victor Grifols Deu serves as CoChief Executive Officer, Executive Director of Grifols, S.A. since January 1, 2017. He joined the Company in 2001 as an analyst in the Planning and Control Department of the Company. In 2008 he became the director of the Planning and Control Department and was also appointed member of the Executive Committees. He was part of the team that analysed and was responsible for the integration of the operations after the acquisition of Alpha Therapeutics, Talecris Biotherapeutics and Novartis Transfusion Diagnostic Unit. Mr. Grifols Deu is a member of the board of Araclon Biotech S.L.. He graduated in Business Administration and Management from the Universitat Ramon Llull Sarri Chemical Institute and holds a postgraduate degree in Business Administration and Management from Michael Smurfit Business School in Dublin. since 2017.
Tenure 7 years
Address Avinguda de la Generalitat, 152, Barcelona, Spain, 08174
Phone34 935 712 200
Webhttps://www.grifols.com

Grifols SA Management Efficiency

The company has return on total asset (ROA) of 0.0214 % which means that it generated a profit of $0.0214 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.022 %, meaning that it created $0.022 on every $100 dollars invested by stockholders. Grifols SA's management efficiency ratios could be used to measure how well Grifols SA manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to 0.04 in 2024. Return On Assets is likely to drop to 0 in 2024. At this time, Grifols SA's Asset Turnover is comparatively stable compared to the past year.
The company currently holds 10.12 B in liabilities with Debt to Equity (D/E) ratio of 1.14, which is about average as compared to similar companies. Grifols SA ADR has a current ratio of 2.63, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Grifols SA until it has trouble settling it off, either with new capital or with free cash flow. So, Grifols SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Grifols SA ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Grifols to invest in growth at high rates of return. When we think about Grifols SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 5 records

CEO Age

Marcel HilmerForsys Metals Corp
N/A
Jeffrey SchweitzerUnivest Pennsylvania
44
Todd NelsonCECO Environmental Corp
58
Kenneth StannardEncore Capital Group
52
Kenneth VecchioneEncore Capital Group
60
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company was founded in 1940 and is headquartered in Barcelona, Spain. Grifols SA operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 27584 people. Grifols SA ADR (GRFS) is traded on NASDAQ Exchange in USA. It is located in Avinguda de la Generalitat, 152, Barcelona, Spain, 08174 and employs 23,744 people. Grifols SA is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Grifols SA ADR Leadership Team

Elected by the shareholders, the Grifols SA's board of directors comprises two types of representatives: Grifols SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Grifols. The board's role is to monitor Grifols SA's management team and ensure that shareholders' interests are well served. Grifols SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Grifols SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Antonio Pares, Director of Planning and Control
Alberto Roura, President Division
Carsten Schroeder, President Of The Diagnostic Division
Albert Roura, CEO of Laboratorios Grifols SA
Lafmin Morgan, President Of The Bioscience And Hospital Division
Juan Roura, Vice President of Production, Executive Director
Eva Tubau, Chief Scientific Officer
Anna Lluch, Independent Director
Carlos Fernandez, Deputy Industrial Vice President
Jose Gras, Director, Representative of Thorthol Holdings BV
Maria Llano, Chief Officer
Edgar Jannotta, Independent Director
Vicente Torre, Chief Officer
Mateo Humbert, Director of Human Resources
Montserrat Calvo, Chief Administrative Officer, Controller
Montserrat Llamas, Chief Officer
Ramon Roca, Vice-President of Marketing and Sales and Executive Director
Vctor Deu, CoCEO Director
David Bell, Vice President of Corporate Operations and Development of Grifols Inc and United States Subsidiaries
Victor Deu, Co-CEO, Executive Director
Luis Bobadilla, Independent Director
Inigo Mardones, Director
Thomas Glanzmann, CEO Chairman
Carina Lazaro, Independent Director
Joel Abelson, President of North America Commercial Division of Grifols Inc
Steven Mayer, Director
Javier Ribes, CEO of Instituto Grifols SA
Alfredo Guerra, CFO and Corporate VP
Raimon Roura, Non-Member Secretary of the Board
Victor Roura, Chairman, CEO and President and Member of Appointments and Remuneration Committee
Brett Ingersoll, Director
Shinji Wada, President of Plasma Centers of Grifols Inc
Tomas Gelabert, Director
Nuria Lapea, Risk Treasury
Sergio Adell, President Support
M Tubau, Corporate Affairs
Steven JD, Ex Chairman
Marla Salmon, Independent Director
Nuria Barnes, Non-Member Assistant Secretary of the Board
Gregory Rich, President of Grifols Inc and Subsidiaries in the US
Belen Morenes, Independent Director
Nuria Lapena, Director of Shareholder and Investor Relations

Grifols Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Grifols SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Grifols SA ADR is a strong investment it is important to analyze Grifols SA's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Grifols SA's future performance. For an informed investment choice regarding Grifols Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Grifols SA ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.
Note that the Grifols SA ADR information on this page should be used as a complementary analysis to other Grifols SA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Grifols Stock analysis

When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
CEOs Directory
Screen CEOs from public companies around the world
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Grifols SA's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Grifols SA. If investors know Grifols will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Grifols SA listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.787
Earnings Share
0.1
Revenue Per Share
4.849
Quarterly Revenue Growth
0.033
Return On Assets
0.0214
The market value of Grifols SA ADR is measured differently than its book value, which is the value of Grifols that is recorded on the company's balance sheet. Investors also form their own opinion of Grifols SA's value that differs from its market value or its book value, called intrinsic value, which is Grifols SA's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Grifols SA's market value can be influenced by many factors that don't directly affect Grifols SA's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Grifols SA's value and its price as these two are different measures arrived at by different means. Investors typically determine if Grifols SA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Grifols SA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.